40118-17-0

Usage

Uses

Used in Organic Synthesis:
(6-nitro-1,3-benzodioxol-5-yl)acetic acid is used as a key intermediate in the synthesis of various organic compounds. Its unique structure allows for the formation of new chemical bonds and the creation of novel molecules with potential applications in various industries.
Used in Medicinal Chemistry:
(6-nitro-1,3-benzodioxol-5-yl)acetic acid is used as a building block in the development of pharmaceutical drugs and other biologically active compounds. Its structural and chemical properties make it a valuable component in the design and synthesis of new drugs with potential therapeutic effects.
Used in Pharmaceutical Drug Development:
(6-nitro-1,3-benzodioxol-5-yl)acetic acid is used as a potential therapeutic agent for the treatment of various diseases and disorders. Its unique structure and properties may contribute to the development of new drugs with improved efficacy and safety profiles.
Used in Research and Study:
(6-nitro-1,3-benzodioxol-5-yl)acetic acid is used as a subject of ongoing research and study to explore its potential uses and applications. Further investigation into its chemical properties, reactivity, and interactions with other compounds may lead to the discovery of new applications and advancements in various fields.

Upstream product

• 857543-43-2 (6-nitro-benzo[1,3]dioxol-5-yl)-acetic acid amide 
• 77566-54-2 4-allyl-5-nitro-1,2-methylenedioxybenzene 
• 2861-28-1 1,3-benzodioxole-5-acetic acid 

Relevant academic research and scientific papers

Synthesis of 1,3-benzodioxole derivatives containing a amino acid moiety in side chain

The synthesis of the new amino-acyl derivatives starting from a 1,3-benzodioxole unit present in safrole is described. All the synthesised compounds, that could be conveniently prepared in a few steps process, have been characterised by the IR and the 1H-NMR Spectroscopy.

Synthesis, antitumour and antimicrobial activities of new peptidyl derivatives containing the 1,3-benzodioxole system

Two series of 5 and 6-substituted 1,3-benzodioxole peptidyl derivatives were synthesized and evaluated as antitumour and antimicrobial agents. The compounds that could be conveniently prepared in a few steps processes from natural safrole have been charac

Photoactivatable prodrugs of highly potent duocarmycin analogues for a selective cancer therapy

A main problem of common cancer chemotherapy is the occurrence of severe side effects caused by insufficient selectivity of the applied drugs. A possible concept to overcome this limitation is light-driven prodrug monotherapy. The synthesis as well as photochemical and biological evaluation of new photoactivatable prodrugs is described. Best results were obtained with prodrug (S,S)-7 a. The photochemical labile protecting groups in (S,S)-7 a can easily be removed by irradiation with UV-A light in 30 min with a power of only 2 J cm-2. The determination of the in vitro cytotoxicity by using an HTCFA-test reveals a QIC50 value of 8200 and the prodrug is more than two million times less cytotoxic than the corresponding seco-drug (-)-(S,S)-5 with an IC50 value of about 110 fM. The big therapeutic window makes (S,S)-7 a very suitable for its use in selective cancer therapy. Copyright

Synthesis and antitumour evaluation of peptidyl-like derivatives containing the 1,3-benzodioxole system

In the scope of a research program aiming at the synthesis and pharmacological evaluation of novel possible antitumour prototype compounds, we described in this paper the synthesis of peptidyl-like derivatives containing the 1,3-benzodioxole system. The proliferation inhibitors tested against tumour cell lines identified the derivatives tyrosine (4f) and lysine (4g) as the most active among them, presenting IC50 values in micromolar range and are more active than Safrole. For the study on the embryonic development, Safrole did not show any selectivity in this latter assay, which indicates that Safrole acts as a 'cell cycle-nonspecific' inhibitory agent. However, compound 4f presented a fair antimitotic effect, mainly on third cleavage and blastulae stages (38% and 1.7% of normal development, at 10 μg/mL), suggesting a time-dependent activity and a 'cell cycle-specific' agent action. Neither derivatives revealed hemolytic action in assay with mouse erythrocytes.